Pregled bibliografske jedinice broj: 68779
The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial.
The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial. // Blood, 96 (2000), 11. (podatak o recenziji nije dostupan, članak, ostalo)
CROSBI ID: 68779 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-Gimema AML-10 randomized trial.
Autori
De Witte, T ; Suiciu, S ; Zittoun, R ; Resegotti, L ; Liso, V ; Willemze, R ; Belhabri, A ; Amadori, S ; Guistolisi, R ; Labar, B ; Fioritoni, G, Rossi-Ferrini, G ; Leone, G ; Jehn, U ; Keating, S ; Fazi, P ; Rodts, P ; Solbu, G ; Mandelli, F.
Izvornik
Blood 96
(2000), 11;
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
xx
(x)
Sažetak
Xx
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti